SOHO 2023 | Addressing whether AML with monocytic features should be considered a distinct clinical entity
Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, discusses whether acute myeloid leukemia (AML) with monocytic features should be considered a distinct clinical entity, highlighting that patients with this subtype of AML tend to respond less effectively to venetoclax-based regimens. Dr Pollyea also suggests that new treatment approaches should be considered for AML with monocytic features, and concludes by explaining why this subtype should be considered a distinct entity. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
AML with monocytic features is a separate entity- it’s been considered as such by pathologists at least since 1976, when some of the morphologic classification systems were developed. I think the question that we were getting at here was: is it a clinically relevant or clinically significant separate entity? In order for it to be considered as such, I think it has to have a distinct treatment regimen...
AML with monocytic features is a separate entity- it’s been considered as such by pathologists at least since 1976, when some of the morphologic classification systems were developed. I think the question that we were getting at here was: is it a clinically relevant or clinically significant separate entity? In order for it to be considered as such, I think it has to have a distinct treatment regimen. What we have found historically, is there really hasn’t been any reason to treat it any differently. But in the era of venetoclax, it seems as though this is a subset of patients that responds less well to venetoclax. And so if we’re going to be thinking about other treatment approaches for this entity, then I think it should be considered a distinct clinical entity. I think it’s incumbent on us, the research field, to try to find and develop better therapies for this subset of patients that doesn’t seem to respond as well to venetoclax-based regimens.
Read more...
